Lv35
248 积分 2025-02-28 加入
Impact of Payload Hydrophobicity on the Stability of Antibody–Drug Conjugates
12天前
已完结
Bystander effect of antibody–drug conjugates: fact or fiction?
12天前
已完结
Rational design of DXd derivatives for liposomal drug delivery: Towards safer and more effective cancer treatments
12天前
已完结
Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates
12天前
已完结
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
16天前
已完结
Breathing in America: Disease, Progress, and Hope edited by Dean E. Schraufnagel
16天前
已关闭
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
17天前
已完结
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial
17天前
已完结
De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial
17天前
已完结
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
17天前
已完结
皖公网安备34019202002308
